Value based pricing for NHS drugs: An opportunity not to be missed?

Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/4632

Full metadata record

DC Field	Value	Language
dc.contributor.author	Claxton, K	-
dc.contributor.author	Briggs, AH	-
dc.contributor.author	Buxton, MJ	-
dc.contributor.author	Culyer, AJ	-
dc.contributor.author	McCabe, C	-
dc.contributor.author	Walker, S	-
dc.contributor.author	Sculpher, MJ	-
dc.date.accessioned	2010-12-06T12:43:33Z	-
dc.date.available	2010-12-06T12:43:33Z	-
dc.date.issued	2008	-
dc.identifier.citation	BMJ 336(7638): 251-254, Feb 2008	en_US
dc.identifier.issn	0959-8138	-
dc.identifier.uri	http://www.bmj.com/content/336/7638/251	en
dc.identifier.uri	http://bura.brunel.ac.uk/handle/2438/4632	-
dc.description	The official puclished version of the article can be found at the link below	en_US
dc.description.abstract	The policy debate about price, value, and innovation in pharmaceuticals is at a critical stage for the NHS. Karl Claxton and colleagues describe the key principles of value based pricing and consider some of the concerns about such a scheme	en_US
dc.language.iso	en	en_US
dc.publisher	British Medical Journal	en_US
dc.relation.ispartof	The Health Economics Research Group	-
dc.title	Value based pricing for NHS drugs: An opportunity not to be missed?	en_US
dc.type	Article	en_US
dc.identifier.doi	http://dx.doi.org/10.1136/bmj.39434.500185.25	-
Appears in Collections:	Health Economics Research Group (HERG)

Files in This Item:

File	Description	Size	Format
Fulltext.pdf		427.65 kB	Adobe PDF	View/Open